GeneThera Selects Tecan Platform as Standard
News Mar 22, 2006
GeneThera, Inc. has announced that the Company has chosen the Tecan Freedom EVO® system for installation in each testing facility the Company opens in the future as well as in its Wheat Ridge, Colorado lab.
"The Tecan product is a superior system that will allow GeneThera to streamline our live animal blood testing and allow us to automatically run our tests with 100 percent accuracy," said Dr. Tony Milici, CEO.
"We have standardized on the Freedom EVO® system, which will allow for each lab to come on-line much sooner without the delay of training personnel on new products and procedures. All training will be done in our Wheat Ridge facility prior to sending each new system to our international labs."
"We are proud to have GeneThera select Tecan as their equipment and testing partner," said Jeff Aufmann, Tecan's MidWest Sales Manager.
"To have the opportunity to advance GeneThera's live animal testing assay with our product and to work with Dr. Milici throughout GeneThera's labs is of great importance to our Company."
New Inherited Neurodevelopmental Disease DiscoveredNews
Researchers have identified a new inherited neurodevelopmental disease that causes slow growth, seizures and learning difficulties in humans.READ MORE
Bird and Turtle Chromosomes Help Identify Dinosaur DNANews
Researchers have used bird and turtle DNA to extrapolate the chromosome structure of their common ancestor that lived around 260 million years ago – 20 million years before the dinosaurs first emerged. They were then able to trace the evolution of avian and non-avian dinosaur DNA through to the present day.
Over 130 Glaucoma Gene Variants Could Help Predict BlindnessNews
An international study has identified 133 genetic variants that could help predict the risk of developing glaucoma, the world’s leading cause of incurable blindness. The findings are an advance in the fight to tackle the incurable, degenerative condition, which has virtually no symptoms in the early stages, and could lead to a genetic-based screening program.READ MORE